BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-7249 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-7249\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07308392-1208@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-7249: Phase 2 readout est. (NCT07308392)
DESCRIPTION:HRS-7249\, phase 2\, Severe Hypertriglyceridemia.\nStudy: Phase
  II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-
 1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pa
 ncreatitis\nEstimated primary completion: June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/hrs-7249#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07308392
URL:https://assetmemo.bio/drug/hrs-7249#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799688-1208@assetmemo.bio
DTSTAMP:20261121T005648Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:HRS-7249: Phase 2 readout est. (NCT07799688)
DESCRIPTION:HRS-7249\, phase 2\, Hypertriglyceridemia.\nStudy: A Extension 
 Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hyp
 ertriglyceridemia\nEstimated primary completion: 15 October 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hrs-7249#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07799688
URL:https://assetmemo.bio/drug/hrs-7249#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
